APOE and Alzheimer disease: Given the higher prevalence of APOE4 carriers among patients with AD, we prepared both synthetic rHDL-APOE3 and HDL-APOE4 nanoparticles by assembling phospholipids and cholesterol with recombinant human APOE3 or APOE4 (see Fig. 3a for a schematic diagram of their synthesis).